New England Securities’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

New England Securities’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$19K	Hold	375	–	–	0.01%	905
2014 Q3	$17K	Hold	375	–	–	0.01%	975
2014 Q2	$16K	Sell	375 -50	-12%	-$2.03K	0.01%	986
2014 Q1	$18K	Sell	425 -30	-7%	-$1.28K	0.01%	896
2013 Q4	$17K	Sell	455 -550	-55%	-$19.7K	0.01%	880
2013 Q3	$35K	Sell	1,005 -40	-4%	-$1.32K	0.02%	591
2013 Q2	$30K	Buy	+1,045	New	+$29.7K	0.02%	566

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

New England Securities's PBE Position: Q4 2014 in Review

New England Securities held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q4 2014 at 375 shares worth $19K. The position accounts for 0.01% of the portfolio, ranked #905.

New England Securities first reported a position in PBE in Q2 2013 and has held it in 7 quarters since. The position peaked at $35K in Q3 2013. 82 funds tracked by Wall St. Rank hold PBE as of Q4 2014.

New England Securities held 375 shares of Invesco Biotechnology & Genome ETF worth $19K as of Q4 2014.
New England Securities left its Invesco Biotechnology & Genome ETF share count unchanged in Q4 2014.
Invesco Biotechnology & Genome ETF made up 0.01% of New England Securities's portfolio in Q4 2014, its #905 holding.
New England Securities first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 7 quarters since.
New England Securities's Invesco Biotechnology & Genome ETF position peaked at $35K in Q3 2013.
82 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.